Beximco Pharma Challenges Regulator’s Order on Financial Reporting and Board Changes

Beximco Pharmaceuticals Limited Sponsored GDR RegS ( (GB:BXP) ) just unveiled an update.

Beximco Pharmaceuticals PLC has disclosed that the Bangladesh Securities and Exchange Commission has refused its requests to extend deadlines for publishing its Q3 2025, full-year 2025 and Q1 2026 financial results and has ordered the company to convene a board meeting including nine additional independent directors proposed by the regulator. The company has challenged this order via a writ petition in the High Court Division of the Supreme Court of Bangladesh, which has asked the regulator to justify the legality of its directive and will hear the case alongside an existing petition contesting the proposed board appointments; while the company’s shares remain temporarily suspended from trading on AIM, they continue to trade on the Dhaka and Chittagong stock exchanges, and Beximco has pledged to update the market on material developments under its regulatory obligations.

More about Beximco Pharmaceuticals Limited Sponsored GDR RegS

Beximco Pharmaceuticals PLC is a leading Bangladesh-based manufacturer and exporter of generic medicines and active pharmaceutical ingredients, offering a broad portfolio ranging from tablets, capsules and injectables to inhalers, ophthalmic products and insulins. Its state-of-the-art facilities are certified by major global regulators in the US, Europe, Australia, Canada, the GCC and Latin America, and the company serves more than 50 countries while also undertaking contract manufacturing for multinational and global generic drug makers.

Average Trading Volume: 81,430

Technical Sentiment Signal: Buy

See more data about BXP stock on TipRanks’ Stock Analysis page.